Literature DB >> 31654708

Preventive effects of a natural anti-inflammatory agent Salvianolic acid A on acute kidney injury in mice.

Xi Zeng1, Xuehong Chen2, Huan Qin2, Yantao Han2, Xiuping Chen3, Zhiwu Han4, Wenwen Zhao5.   

Abstract

Acute kidney injury (AKI) is an abrupt loss of kidney function with high mortality. Inflammatory is considered driving the progression of AKI. Salvianolic acid A (SA), one of the major ingredients of Salvia miltiorrhiza Bunge, displays plenty of biological effects. Herein, the effect of SA on lipopolysaccharide (LPS)-induced AKI in mice and further related mechanism in inflammatory cells were explored. In vivo experiments demonstrated that SA significantly ameliorated LPS-challenged AKI by preventing glomerulus atrophy and decreasing plasma creatinine and blood urea nitrogen (BUN) levels. Meanwhile, SA significantly decreased the release of serum inflammatory cytokines and blocked macrophage infiltration in damaged renal tissue. In in vitro studies, SA significantly decreased TNF-α and IL-6 release levels and altered the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in LPS-stimulated macrophages, which were consistent with the results from in vivo experiments. Furthermore, SA that bound to Toll-Like Receptor 4 (TLR4) was able to reduce endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) generation in response to LPS stimulation. All silence of TLR4 gene, ROS scavenger and Ca2+ chelator decreased inflammatory cytokines releases. Taken together, SA could be used as a potential therapeutic agent for preventing AKI by suppressing inflammatory responses.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute kidney injury; Inflammatory; Lipopolysaccharide; Oxidative stress; Salvianolic acid A

Mesh:

Substances:

Year:  2019        PMID: 31654708     DOI: 10.1016/j.fct.2019.110901

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  7 in total

1.  Salvianolic Acid A Ameliorates Early-Stage Atherosclerosis Development by Inhibiting NLRP3 Inflammasome Activation in Zucker Diabetic Fatty Rats.

Authors:  Quanxin Ma; Qinqin Yang; Jiaojiao Chen; Chen Yu; Lizong Zhang; Weimin Zhou; Minli Chen
Journal:  Molecules       Date:  2020-02-28       Impact factor: 4.411

2.  Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis against Kidney Injury.

Authors:  Wenjiu Yang; Jing Han; Shuo Gong; Jun Zhao; Tengbo Yu; Jinfeng Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-29       Impact factor: 2.629

3.  Histomorphological and ultrastructural cadmium-induced kidney injuries and precancerous lesions in rats and screening for biomarkers.

Authors:  Xichen Wan; Zelong Xing; Jin Ouyang; Hui Liu; Chengquan Cheng; Ting Luo; Shiqun Yu; Li Meihua; Shaoxin Huang
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

4.  Salvianolic acid A alleviates lipopolysaccharide-induced disseminated intravascular coagulation by inhibiting complement activation.

Authors:  Qi-Yun Zhang; Jing Guo; Lin Xu; Ying Wei; Shu-Ting Zhou; Qing-Yu Lu; Li Guo; Qian-Yun Sun
Journal:  BMC Complement Med Ther       Date:  2022-09-20

5.  Lycopene-Loaded Bilosomes Ameliorate High-Fat Diet-Induced Chronic Nephritis in Mice through the TLR4/MyD88 Inflammatory Pathway.

Authors:  Chang Liu; Yu Liu; Ciwan Wang; Yahui Guo; Yuliang Cheng; He Qian; Yong Zhao
Journal:  Foods       Date:  2022-09-30

6.  Salvianolic Acid D Alleviates Cerebral Ischemia-Reperfusion Injury by Suppressing the Cytoplasmic Translocation and Release of HMGB1-Triggered NF-κB Activation to Inhibit Inflammatory Response.

Authors:  Wen Zhang; Junke Song; Wan Li; Dewen Kong; Yu Liang; Xiaoyue Zhao; Guanhua Du
Journal:  Mediators Inflamm       Date:  2020-01-22       Impact factor: 4.711

7.  Therapeutic Targeting of GSK3β-Regulated Nrf2 and NFκB Signaling Pathways by Salvianolic Acid A Ameliorates Peritoneal Fibrosis.

Authors:  Fan Zhou; Lan Yao; Xiaoqing Lu; Yubao Li; Xingmin Han; Pei Wang
Journal:  Front Med (Lausanne)       Date:  2022-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.